FDA seeks more data on MannKind's inhaled insulin

BOSTON (Reuters) - U.S. regulators have requested more information on an inhaled insulin device being developed by MannKind Corp, sending the company's shares down 24.7 percent.

Tue 16 Mar 10 from Reuters

FDA seeks more data on MannKind's inhaled insulin, Mon 15 Mar 10 from Reuters